Alibaba Health Information Technology Ltd. (HK:0241)
:0241
Want to see HK:0241 full AI Analyst Report?
Top Page
Alibaba Health Information Technology
(0241)
Select Model
Select Model
Rating:67Neutral
Price Target:
HK$5.00
▼(-10.39% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily supported by strong financial performance (improving margins, strong free cash flow growth, and very low leverage). However, the overall rating is held back by weak technical signals, with the stock trading below key moving averages and negative MACD despite oversold readings. Valuation is reasonable but not clearly compelling, and no earnings call or corporate event data was available to adjust the outlook.
Positive Factors
Revenue Growth
Consistent revenue growth of ~8% demonstrates expanding customer adoption and platform traction across pharma sales and digital services. Durable top-line expansion supports scale economics, recurring platform fees, and a larger funnel for cross-selling over the next 2-6 months.
Negative Factors
Modest Net Margin
Despite improvement, a sub-5% net margin remains modest for a platform-focused healthcare business. Limited net profitability constrains the firm's ability to absorb pricing competition, scale sales/marketing aggressively, or weather regulatory-driven cost increases over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth of ~8% demonstrates expanding customer adoption and platform traction across pharma sales and digital services. Durable top-line expansion supports scale economics, recurring platform fees, and a larger funnel for cross-selling over the next 2-6 months.
Read all positive factors
Alibaba Health Information Technology (0241) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$70.66B
Dividend YieldN/A
Average Volume (3M)83.52M
Price to Earnings (P/E)19.5
Beta (1Y)2.21
Revenue Growth16.14%
EPS Growth53.86%
CountryHK
Employees1,422
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.10
Shares Outstanding16,175,301,000
10 Day Avg. Volume99,710,369
30 Day Avg. Volume83,522,295
Financial Highlights & Ratios
PEG Ratio1.17
Price to Book (P/B)4.33
Price to Sales (P/S)2.31
P/FCF Ratio51.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.11Price Target Upside9.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.17
Revenue Forecast (FY)HK$39.63B
Alibaba Health Information Technology Business Overview & Revenue Model
Company Description
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. It offers...
How the Company Makes Money
Alibaba Health’s revenue model centers on monetizing healthcare product sales and platform-enabled services. Key revenue streams include: (1) Pharmaceutical and healthcare product sales (direct sales): The company earns revenue by selling prescrip...
Alibaba Health Information Technology Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.91B | 30.60B | 27.03B | 26.76B | 20.58B | 15.52B |
| Gross Profit | 8.05B | 7.43B | 5.90B | 5.70B | 4.11B | 3.62B |
| EBITDA | 2.16B | 1.62B | 999.05M | -24.48M | -188.12M | 52.14M |
| Net Income | 1.92B | 1.43B | 883.48M | 535.65M | -265.56M | 348.59M |
Balance Sheet | ||||||
| Total Assets | 23.26B | 21.18B | 19.71B | 20.75B | 19.20B | 17.74B |
| Cash, Cash Equivalents and Short-Term Investments | 9.39B | 8.10B | 9.55B | 10.92B | 10.55B | 11.64B |
| Total Debt | 75.91M | 35.52M | 82.17M | 77.80M | 135.41M | 37.74M |
| Total Liabilities | 5.70B | 4.87B | 5.19B | 5.60B | 5.13B | 3.46B |
| Stockholders Equity | 17.57B | 16.31B | 14.54B | 15.17B | 14.10B | 14.30B |
Cash Flow | ||||||
| Free Cash Flow | 1.60B | 1.38B | 1.06B | 250.08M | 409.43M | 992.35M |
| Operating Cash Flow | 1.60B | 1.40B | 1.08B | 255.69M | 424.36M | 1.01B |
| Investing Cash Flow | -757.92M | -2.60B | -4.88B | -532.44M | 1.87B | -4.96B |
| Financing Cash Flow | -52.74M | -72.52M | -1.98B | -111.28M | -58.63M | 8.92B |
Alibaba Health Information Technology Technical Analysis
Negative
5.58
Price Trends
5.33
Negative
5.57
Negative
5.60
Negative
Market Momentum
-0.18
Negative
43.67
Neutral
52.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0241, the sentiment is Negative. The current price of 5.58 is above the 20-day moving average (MA) of 4.74, above the 50-day MA of 5.33, and below the 200-day MA of 5.60, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 43.67 is Neutral, neither overbought nor oversold. The STOCH value of 52.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0241.
Alibaba Health Information Technology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$6.39B | 19.61 | 6.83% | 2.72% | 15.04% | 5.57% | |
67 Neutral | HK$70.66B | 19.51 | 11.49% | ― | 16.14% | 53.86% | |
60 Neutral | HK$65.45B | 6.70 | 7.64% | 2.67% | 6.45% | 35.60% | |
57 Neutral | HK$57.64B | 7.82 | 8.62% | 3.75% | -1.57% | 1.55% | |
55 Neutral | HK$23.24B | 70.40 | 3.83% | ― | 13.84% | 146.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$6.52B | -110.24 | -2.28% | ― | -4.99% | 47.18% |
* Healthcare Sector Average
HK:0241
Alibaba Health Information Technology
4.37
-0.78
-15.15%
HK:1833
Ping An Healthcare and Technology Company
10.75
3.20
42.38%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.76
1.51
14.75%
HK:1099
Sinopharm Group Co
18.47
1.20
6.96%
HK:2158
Yidu Tech, Inc.
6.12
0.20
3.38%
HK:2192
Medlive Technology Co., Ltd.
8.64
-3.10
-26.41%
Alibaba Health Information Technology Corporate Events
Alibaba Health Grants 3.88 Million RSUs to Employees Under 2024 Share Scheme
Mar 13, 2026
Alibaba Health Information Technology has granted 3,881,600 restricted share units to 20 employees under its 2024 Share Award Scheme, with each unit representing the right to receive one share upon vesting. The awards, which carry no purchase pric...
Alibaba Health Shareholders Approve Higher Marketing Caps Under Alimama Framework
Dec 30, 2025
Alibaba Health Information Technology Limited announced that shareholders approved an ordinary resolution at a special general meeting held on 30 December 2025 in Hangzhou, with the measure passed by an overwhelming majority via poll. The resoluti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.